Jeffrey Bluestone exits Parker and switches focus back to autoimmune diseases in cell therapy 2.0 launch
Jeffrey Bluestone is returning to the scientific field where he forged his reputation as a drug hunter and top investigator.
The prominent scientist has handed in his walking papers as CEO of the high profile Parker Institute for Cancer Immunotherapy, switched to the adjunct faculty at UCSF and is now launching a new company, where he plans to take a hands-on role in the development of new cell therapies for autoimmune and degenerative diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 72,800+ biopharma pros reading Endpoints daily — and it's free.